Blue Owl Capital has announced an investment of up to $262.5 million in ITM Isotope Technologies Munich SE to support the development of innovative radiopharmaceutical therapies for cancer treatment.
Target Information
Blue Owl Capital has committed to a term loan facility of up to $262.5 million for ITM Isotope Technologies Munich SE, a pioneering company in the field of radiopharmaceuticals. Headquartered in Munich, Germany, ITM focuses on developing advanced radiopharmaceutical therapeutics and diagnostics specifically designed for challenging tumor types, positioning itself as a leader in innovative cancer treatments.
With a strong emphasis on research and development, ITM Isotope Technologies is dedicated to improving patient outcomes through specialized therapies that offer targeted treatment approaches, thereby enhancing the effectiveness of cancer care.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Germany
The German biotechnology sector has experienced significant growth and innovation, particularly in the areas of pharmaceuticals and life sciences. Germany is characterized by
Similar Deals
European Investment Bank → Smart Reporting
2023
Verdane → Clue
2026
Blue Owl Capital
invested in
ITM Isotope Technologies Munich SE
in 2025
in a Venture Debt deal
Disclosed details
Transaction Size: $263M